Occoris - Self Activating Smart Inhaler

将肺沉积靶向病变呼吸道的能力受到患者正确操作该设备的认知能力、他/她的吸气轮廓以及吸入器的雾化机制的影响。该项目的重点是开发一种名为Occoris的新型气溶胶产生装置。与传统的pmdi不同，Occoris不需要推进剂，并且可以回收。与DPI类似，气雾剂是由患者按需生成的。然而，由于药物配方是预先包装在加压水泡中的，雾化作用是自我激活的，不是由强力吸入驱动的。当患者吸入时，水泡破裂，并释放出一种适合深度呼吸的细小气雾剂。因此，Occoris有潜力用于：1.药物输送与吸入的协调；2.与PMDIs(甚至呼吸驱动的PMDIs)相比，最大限度地减少喉咙沉积；3.最大限度地减少患者之间肺功能引起的肺沉积的变异性；4.大剂量DPI产品的气雾剂剂量和特性的一致性。在这项研究计划中，我们将寻求开发一种机制，通过控制患者的吸气流速和吸入周期中气雾剂颗粒的释放速率，将药物气雾剂靶向肺部的病变区域。DPI药物输送的这一独特成就来自于Occoris泡罩设计的新的雾化机制。将使用人体吸入模拟器来研究气雾剂的产生，以再现从OLD患者记录的吸入曲线。在先进分析方法的开发支持下，药物配方将在研究中实现高分散性，以测试化学稳定性和与Occoris成分的兼容性。泡罩包装组件将使用透气纤维网来支撑铝泡内的配方，铝泡被设计成在患者吸入时破裂。从这些研究中获得的知识将被转化为产品，最大限度地减少喉咙沉积，并最大限度地以治疗肺病的治疗性气雾剂为靶点。

The ability to target lung deposition to the diseased airways is influenced by the patient's cognitive ability to handle thedevice correctly, his/her inspiratory profile, and the mechanism of aerosolization of the inhaler. This project focuses on thedevelopment of a novel aerosol generation device called Occoris. Unlike conventional pMDIs, Occoris has no need forpropellants and is recyclable. Similar to DPIs, the aerosol is generated on-demand by the patient. However, because thedrug formulation is pre-packaged in pressurized blisters, the aerosolization is self-activating and is not driven by a forcefulinhalation. When the patient inhales, the blister ruptures, and releases a fine aerosol of drug suitable for deep lunginhalation. Occoris therefore has potential for:1. Coordination of drug delivery with inhalation;2. Minimized throat deposition, compared to pMDIs (even breath-actuated pMDIs);3. Minimized pulmonary function-derived variability of lung deposition between patients;4. Consistency of aerosol dose and properties for high-dose DPI products.In this research programme, we will seek to develop a mechanism to target drug aerosols to diseased regions of the lungthrough controlling patient's inspiratory flow rate and the release rate of aerosol particles during an inhalation cycle. Thisunique achievement for DPI drug delivery derives from the novel aerosolization mechanism of the Occoris blister design.Aerosol generation will be studied using a human inhalation simulator to reproduce inhalation profiles recorded from OLDpatients. Drug formulations will be engineered to achieve high dispersibility in studies supported by the development ofadvanced analytical methods that test for chemical stability and compatibility with Occoris components. Blister packingcomponents will be engineered using air-permeable fibre meshes to support the formulations within aluminium blisters thatare designed to rupture when a patient inhales. The knowledge gained from these studies will be translated into productsthat minimize throat deposition and maximize deep lung targeting of therapeutic aerosols for the treatment of lungdiseases.